QSAM Biosciences effects 1-for-2,000 reverse stock split; shares reduced to ~2,127

QSAM Biosciences, Inc.

Reverse split effective May 2, 2024, converting each 2,000 shares into 1 share.
Outstanding shares reduced to approximately 2,127 shares from pre-split count.
Fractional shares compensated with cash (~$13,210.58 per fractional) plus one CVR.
Reverse split is a condition precedent for pending merger with Telix Pharmaceuticals.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

QSAM Biosciences, Inc.: Effected a 1-for-2,000 reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2024-05-02).

Change: charter amendment
Effective: 2024-05-02

Exact text from the filing

QSAM filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (“ Certificate of Amendment ”) with the Secretary of State of the State of Delaware, to effectuate the Reverse Split with an effective date of May 2, 2024

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001493152-24-017494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.